Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 2 hours ago
- 1 min read
11/05/2026
Fate Therapeutics showcased FT819 clinical activity in SLE without the use of conditioning chemotherapy at the 2026 ASGCT Annual Meeting (Ref)
Fate Therapeutics showcased FT819 (an Off-the-shelf CD19 CAR T-cell therapy) which was being investigated in a Phase 1/ NCT06308978 study in patients with moderate-to-severe systemic lupus erythematosus (SLE) including lupus nephritis and extrarenal lupus.
The data showed that in regimen B of the Phase 1 study a single dose of FT819 administered without conditioning chemotherapy and in the presence of background therapy demonstrated meaningful clinical responses at dose level 1 in patients with active SLE, with 3 of 3 patients achieving SRI-4 and 2 of 3 patients achieving LLDAS.
Preliminary data demonstrated that treatment with FT819 without conditioning chemotherapy and in the presence of background therapy can drive comprehensive changes in B cell repertoire that were associated with clinical benefit, alongside a favorable safety profile.
